Literature DB >> 24108565

Novel antiplatelet drugs in clinical development.

M Ungerer1, G Münch.   

Abstract

The clinical value of antiplatelet compounds strongly depends on the benefit-risk balance between their anti-thrombotic effects and the bleeding risk they incur. This ratio is especially important in the treatment of cerebro-vascular disease. Several novel compounds in clinical development hold promise to improve this benefit-risk ratio.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 24108565     DOI： 10.1160/TH13-02-0084

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN： 0340-6245            Impact factor:   5.249


  8 in total

Review 1.  Novel anti-platelet agents in acute coronary syndrome: mechanisms of action and opportunities to tailor therapy.

Authors:  Neha Quatromoni; Sony Tuteja; Daniel M Kolanksy; William H Matthai; Jay Giri
Journal:  Curr Atheroscler Rep       Date:  2015-05       Impact factor: 5.113

Review 2.  Perspective: Tyrosine phosphatases as novel targets for antiplatelet therapy.

Authors:  Lutz Tautz; Yotis A Senis; Cécile Oury; Souad Rahmouni
Journal:  Bioorg Med Chem       Date:  2015-04-04       Impact factor: 3.641

3.  The effect of the EP3 antagonist DG-041 on male mice with diet-induced obesity.

Authors:  Ryan P Ceddia; Jason D Downey; Ryan D Morrison; Maria P Kraemer; Sarah E Davis; Jing Wu; Craig W Lindsley; Huiyong Yin; J Scott Daniels; Richard M Breyer
Journal:  Prostaglandins Other Lipid Mediat       Date:  2019-07-02       Impact factor: 3.072

4.  Combined administration of the GPVI-Fc fusion protein Revacept with low-dose thrombolysis in the treatment of stroke.

Authors:  Andreas Reimann; Zhongmin Li; Silvia Goebel; Julia Fassbender; Hans-Peter Holthoff; Meinrad Gawaz; Götz Münch; Martin Ungerer
Journal:  Heart Int       Date:  2016-04-25

5.  ADPase CD39 Fused to Glycoprotein VI-Fc Boosts Local Antithrombotic Effects at Vascular Lesions.

Authors:  Heidrun Degen; Oliver Borst; Melanie Ziegler; Ann-Katrin Mojica Munoz; Janina Jamasbi; Britta Walker; Silvia Göbel; Julia Fassbender; Kristin Adler; Richard Brandl; Götz Münch; Reinhard Lorenz; Wolfgang Siess; Meinrad Gawaz; Martin Ungerer
Journal:  J Am Heart Assoc       Date:  2017-07-27       Impact factor: 5.501

Review 6.  Antithrombotic Agents and Cancer.

Authors:  Annalisa Bruno; Melania Dovizio; Stefania Tacconelli; Annalisa Contursi; Patrizia Ballerini; Paola Patrignani
Journal:  Cancers (Basel)       Date:  2018-07-31       Impact factor: 6.639

Review 7.  Targeting GPVI as a novel antithrombotic strategy.

Authors:  Robert K Andrews; Jane F Arthur; Elizabeth E Gardiner
Journal:  J Blood Med       Date:  2014-05-21

Review 8.  Anti-platelet drugs and their necessary interaction with endothelial mediators and platelet cyclic nucleotides for therapeutic efficacy.

Authors:  Rebecca B Knowles; Timothy D Warner
Journal:  Pharmacol Ther       Date:  2018-08-04       Impact factor: 12.310
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.